gz4

GZ4 is a Ca2+ currents inhibitor, acting on cell surface channels.

Ibiglustat (L-Malic acid) (Ibiglustat L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson's disease, SRT in Fabry's and Gaucher's.

Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant inhibitor of glucosylceramide synthase (GCS) utilized in the investigation of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.

Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.

Gatralimab (GZ-402668) is a next-generation humanized anti-CD52 monoclonal antibody for which phase 1 clinical trial data indicate it successfully achieves the intended pharmacodynamic effect of lymphocyte depletion followed by subsequent repopulation, all with an acceptable safety profile, supporting its further investigation about relapsing-remitting multiple sclerosis (MS).